Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

436P - Clinicopathological characteristics and outcomes of adolescent and young adult (AYA) melanoma: Results from an Asian perspective


22 Nov 2020


e-Poster Display Session


Cancer in Adolescents and Young Adults (AYA)

Tumour Site



Wei Lin Goh


Annals of Oncology (2020) 31 (suppl_6): S1407-S1415. 10.1016/annonc/annonc368


W.L. Goh, J. Hong, E.Y.T. Wong, E.W.Y. Chang, V.S. Yang, J. Chiang, J.Y. Chan, N. Somasundaram, M. Farid, E.Y.L. Poon

Author affiliations

  • Division Of Medical Oncology, National Cancer Centre Singapore, 169610 - Singapore/SG


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 436P


AYA melanomas (diagnosed 16-39 years) are rare but rising in incidence. It is not well-understood how they differ from adult melanomas. We aim to describe the demographics, clinic-molecular characteristics and outcomes from our institution.


We retrospectively reviewed all melanoma patients diagnosed between 16 and 39 years old (y) who presented to the National Cancer Centre Singapore from 1 January 2000 to 31 March 2019.


There were 74 patients (41 females, 33 males). 51.4% (n=38) were Chinese, 9.5% Caucasians, 6.8% Malays and the rest of other ethnicity. Across age groups, 9 patients were 16-23 y (12.2%); 26 between 24-31y (35.1%) and 39 between 32-39y (52.7%). The most common subtype was cutaneous melanoma (46%, n=34). 31 (41.9%) patients had BRAF testing. 46.4% (n=13) had BRAF V600E mutation and 1 had BRAF V600K. 20 (27.0%) were tested for cKIT, with none having mutations. 51.4% (n=38) had stage I/II disease (American Joint Committee on Cancer 7th Edition), 16 with stage III and 10 had stage IV. Common metastatic sites were lungs, lymph nodes and liver. 25 (33.8%) patients had sentinel lymph node biopsy (SLNBx), with 5 having lymph node dissection. Among those with SLNBx, 4, 13 and 5 patients had Breslow depths of <1mm, 1-4mm and >4mm respectively. The median depth was 2.7mm (range 0.25–9mm). 7 (9.5%) had first-line systemic therapy, with 5 (2 stage IV; 2 stage III and 1 unknown) receiving immunotherapy. 2 (stage IV) had combination chemotherapy (Dacarbazine/Cisplatin and Paclitaxel/Bevacizumab/Caroboplatin). None received BRAF inhibitors. The median overall survival (OS) is 2.7y (range 0.1–17.7y) for all and 1y for metastatic disease. The 5y OS is 34.5%. The breakdown is shown in the table. Table: 436P

Survival by age and stage

Number Median OS p-value
16-23y 9 4.53 =0.15
24-31y 26 4.15
32-39y 39 2.51
Stage I-III 54 3.25 <0.001
Stage IV 10 1.01


Routine BRAF/cKIT testing commenced in 2010 and immunotherapy started only in 2017, contributing to outcomes we see. Poorer survival is associated with higher stage (p<0.001). Further studies are needed to elucidate potential biological and cancer-specific differences between AYAs and adult melanoma population.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.